News & Updates

Show Multimedia Only

Which anticoagulation intensity works best for Asians with mitral stenosis?

08 Aug 2025 by

The standard intensity for anticoagulation is enough to protect adult southeast Asians with moderate-to-severe rheumatic mitral stenosis (MS) against thromboembolism, with an acceptable risk of major bleeding, according to a study.

Which anticoagulation intensity works best for Asians with mitral stenosis?

08 Aug 2025

More walking, less low back pain issues

06 Aug 2025 by

Walking a longer distance or for a longer time can reduce the risk of developing chronic low back pain.

More walking, less low back pain issues

06 Aug 2025

Bimekizumab shows long-term benefits across axSpA spectrum

02 Aug 2025 by

Treatment with bimekizumab showed sustained efficacy for up to 3 years in patients with nonradiographic (nr) and radiographic (r) axial spondyloarthritis (axSpA), based on a pooled analysis of the two phase III studies (BE MOBILE 1 and 2) and combined open-label extension (OLE) study presented at EULAR 2025.

Bimekizumab shows long-term benefits across axSpA spectrum

02 Aug 2025

Disease-related brain activation forecasts TNF inhibitor response in RA

30 Jul 2025

In patients with rheumatoid arthritis (RA), high disease-associated central nervous system (CNS) pain activation on functional MRI (fMRI) brain scan may help predict clinical response to TNF inhibitor treatment, as shown in a phase III study.

Disease-related brain activation forecasts TNF inhibitor response in RA

30 Jul 2025

Secukinumab may reverse and prevent joint damage in psoriatic arthritis

30 Jul 2025 by

Secukinumab may facilitate partial erosion repair and prevent enthesiophyte progression in patients with psoriatic arthritis (PsA), according to a phase IV randomized clinical trial (RCT).

Secukinumab may reverse and prevent joint damage in psoriatic arthritis

30 Jul 2025

Inebilizumab reduces flare risk in IgG4-RD patients across demographics

30 Jul 2025 by

Treatment with inebilizumab reduced the risk of disease flares in patients with immunoglobulin G4-related disease (IgG4-RD) irrespective of sex, age, or race, according to a subgroup analysis of the phase III MITIGATE study presented at EULAR 2025.

Inebilizumab reduces flare risk in IgG4-RD patients across demographics

30 Jul 2025

Sarilumab helps improve patient-reported outcomes in relapsing polymyalgia rheumatica

24 Jul 2025

In the treatment of patients with relapsing polymyalgia rheumatica who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper, the use of sarilumab appears to produce clinically important improvements in health-related quality of life and patient-reported outcomes, according to the results of a phase III study.

Sarilumab helps improve patient-reported outcomes in relapsing polymyalgia rheumatica

24 Jul 2025

Apremilast trims fat mass, reducing CV events in PsA

23 Jul 2025

Treatment with apremilast results in fat mass reduction among patients with psoriatic arthritis (PsA), indicating positive cardiovascular (CV) and metabolic effects, which may lower the risk of CV events, a recent study has shown.

Apremilast trims fat mass, reducing CV events in PsA

23 Jul 2025

Delays, higher costs in tocilizumab therapy add to burden of GCA

23 Jul 2025

Significant delays occur in the initiation of tocilizumab (TCZ) therapy among patients with giant cell arteritis (GCA), reports a US study.

Delays, higher costs in tocilizumab therapy add to burden of GCA

23 Jul 2025

Fatigue, sleep disturbance hound patients with PMR

22 Jul 2025

In addition to the pain and stiffness that polymyalgia rheumatic (PMR) brings, patients are also burdened by persistent fatigue and sleep disturbance, reveals a study.

Fatigue, sleep disturbance hound patients with PMR

22 Jul 2025

News & Updates

Filter by Specialty:

Specialty:

Which anticoagulation intensity works best for Asians with mitral stenosis?

Which anticoagulation intensity works best for Asians with mitral stenosis?

More walking, less low back pain issues

More walking, less low back pain issues

Bimekizumab shows long-term benefits across axSpA spectrum

Bimekizumab shows long-term benefits across axSpA spectrum

Disease-related brain activation forecasts TNF inhibitor response in RA

Disease-related brain activation forecasts TNF inhibitor response in RA

Secukinumab may reverse and prevent joint damage in psoriatic arthritis

Secukinumab may reverse and prevent joint damage in psoriatic arthritis

Inebilizumab reduces flare risk in IgG4-RD patients across demographics

Inebilizumab reduces flare risk in IgG4-RD patients across demographics

Sarilumab helps improve patient-reported outcomes in relapsing polymyalgia rheumatica

Sarilumab helps improve patient-reported outcomes in relapsing polymyalgia rheumatica

Apremilast trims fat mass, reducing CV events in PsA

Apremilast trims fat mass, reducing CV events in PsA

Delays, higher costs in tocilizumab therapy add to burden of GCA

Delays, higher costs in tocilizumab therapy add to burden of GCA

Fatigue, sleep disturbance hound patients with PMR

Fatigue, sleep disturbance hound patients with PMR